ACIU - CONSENSUS CO - AC Immune

The production capacities of AC Immune (ACIU) partners are fully prepared for the release of commercial vaccines, and equipment wear is strictly monitored. Business revenues are based on the implementation of neurotherapy, specifically treatments for Parkinson's and Alzheimer's diseases. The quotes provided below, where the consensus forecast stands at 8.59, complement the staffing data: the company attracts top neurobiologists thanks to its advanced facility in Switzerland.

This indicator represents the arithmetic mean of target prices from leading analysts, reflecting aggregated market expectations regarding the fair value of assets. By analyzing the consensus valuation trend, an investor can assess the resilience of AC Immune (ACIU) to binary trial risks, where stable valuations confirm the significance of strategic partnerships with pharma behemoths and their ability to support the company's capitalization.